AbbVie stock heads into the open after a 1.8 percent NYSE gain
Published on 09/16/2026 at 08:20 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
AbbVie stock closed at USD 261.77 on the NYSE on September 14, 2026, marking a 1.81 percent gain versus its prior close and trading near its recent highs. The shares moved within an intraday range between USD 260.10 and USD 264.65 during that session, with the close sitting close to the upper end of that band.
September 14, 2026 in numbers
AbbVie Inc. (ISIN US00287Y1091, NYSE: ABBV) ended the September 14, 2026 session at USD 261.77 on the NYSE after rising 1.81 percent from a prior close of USD 257.12, according to price data compilations on Investing.com and a stock-price overview cited by Forbes. The intraday trading range stretched from a low of USD 260.10 to a high of USD 264.65, placing the closing quote closer to the high than the low and underscoring sustained buying interest into the end of the session. As summarized by Ad-hoc-news.de, the advance left the shares trading close to a recent 52-week high around the mid-USD 260s, with robust trading volume underpinning the move. In the same report, the outlet highlighted that AbbVie had raised its quarterly cash dividend to USD 1.73 per share, payable on November 16, 2026, and that this higher payout, together with double-digit revenue growth in the latest quarter, contributed to the stock’s positive tone as of mid-September 2026.
For the second quarter of 2026, AbbVie reported earnings per share of USD 3.65, slightly ahead of the analyst consensus of USD 3.61, a beat of USD 0.04 per share, as noted by Ad-hoc-news.de in its summary of earnings data drawn from MarketBeat. The same coverage pointed out that AbbVie issued guidance for third-quarter 2026 earnings per share in a range of USD 3.84 to USD 3.88, which helped frame investor expectations for the second half of the year and supported sentiment in the stock. Against this backdrop, AbbVie’s 1.81 percent gain on September 14, 2026 contrasted with broader United States equity benchmarks that struggled amid concerns about interest-rate policy, as evidenced by market wraps indicating continued pressure on key indices.
Outlook today
Today, AbbVie enters the new session without a scheduled earnings release but with investors still weighing the implications of its recent dividend increase and guidance for third-quarter 2026 profit, themes that featured prominently in the coverage by Ad-hoc-news.de. Sector-specific developments in pharmaceuticals and biotechnology, including commentary on AbbVie’s post-Humira growth strategy and immunology pipeline reported by MarketBeat, may also shape sentiment as trading gets under way. More broadly, United States equity futures and upcoming macroeconomic data releases relating to inflation and interest-rate expectations, referenced in recent Wall Street market wraps from outlets such as the Pittsburgh Post-Gazette, could influence risk appetite across large-cap healthcare names and provide external cues for AbbVie stock today.
